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Abstract 
 
Introduction 
It has been estimated that solid-dosage forms constitute about 80% of all 
pharmaceutical dosage forms, used to provide systemic administration of 
therapeutic agents. The matrix tablet is the most effective type of tablet in 
controlling drug release from tablet and so into systemic circulation, using 
polymers to perform this action.  
Objectives 
The aim of this study is to investigate that both, drug and polymer solubility 
properties and the difference in polymer source play a role in drug dissolution and 
diffusion from matrix tablets.  
Methods 
In this study, the   full factorial was selected as an experimental design and 
utilized to examine the effects of three variables (set at two levels) on the physical 
performance of matrix tablets. These variables were the source of medium 
viscosity grade (4000 cps) of hydroxypropyl methylcellulose (Germany and 
China), source of polyvinyl pyrrolidone (K-30) (China and Germany) and drug 
solubility (free soluble and sparingly soluble drugs). Matrix tablets within 
experimental design runs were prepared by direct compression with equal ratios of 
drug and polymer, using laboratory tableting machine. Produced matrices were 
subjected to hardness, friability, swelling, erosion and drug release tests.  
Results 
The results have indicated that for insoluble drug, hydrophilic polymer has a 
profound effect on increasing the swelling profile of matrix systems compared to 
hydrophobic one. Moreover, variation in polymers source was shown to have a 
significant effect on tablet hardness and drug release behavior of both soluble and 
insoluble drugs. Furthermore, the hydrophilic polymer was found to be more 
efficient, compared to hydrophobic polymer, in controlling drug dissolution rate 
and so the drug release kinetics of tablet.   
 ملخص الاطروحة
 
المقدمة 
شناه اىَسرحضشاخ ٍِ مو أ%  08ذشٍش اىرقذٌشاخ إىى أُ اىَسرحضشاخ اىظٍذلاٍّح اىظيثح ذشنو ح٘اىً 
أقشاص اىَاذشمس ًٕ أمصش اّ٘اع الأقشاص . اىظٍذلاٍّح اىَسرخذٍح لإٍذاد اىعسٌ داخيًٍا تاىَ٘اد اىَعاظيح
ٗتاىراىً ىذاخو اىعسٌ، ٗ رىل تاسرخذاً اىث٘ىٍَشاخ  فاعيٍح فً اىرحنٌ فً خشٗض اىَادج اىَعاىعح ٍِ اىقشص 
 . لإحذاز ٕزا اىرغٍٍش
 
 الأهداف 
الاخرلاف اىَادج اىَعاىعح ٗ ىث٘ىٍَش ٌٗح هخظائض اىزٗتاُاه :اىرحقق ٍِ أُ ملا ٍِ اىذساسح ٕ٘اىٖذف ٍِ ٕزٓ 
. ٕاٗ خشٗض اىَادج اىَعاىعح ٍِ ،قشاصاىزٗتاٍّح ىلأعَيٍح  ىعة دٗسا فًي ،ىث٘ىٍَشا فً ٍظذس
 
 الطريقة
أشٍش شلاشح ٍرغٍشاخ عيى اىسي٘ك لإخرثاس خ فً ٕزٓ اىذساسح،ذٌ اسرخذاً اىرظٌٍَ الأحظائى اىرعشٌثى 
ٍظذس اىٍٖذسٗمسً تشٗتاٌو ٍٍصاٌو : ٕزٓ اىَرغٍشاخ ًٕ. اىفٍضٌائً ىلأقشاص ٗفق ٍسرٌٍِ٘ ىنو ٍرغٍش
اىَاٍّا (   03-K، ٍظذس اىث٘ىً فٍْاٌو تاٌشٗىٍذُٗ )اىَاٍّا ٗ اىظٍِ( spc 0004سٍيٍي٘ص ٍر٘سط اىي٘صٗظح 
 ).ٗ ضعٍفح اىزٗتاُ فً اىَاء سشٌعح(ٗ رٗتاُ اىَادج اىَعاىعح ) ٗ اىظٍِ
 
ذٌ ذظٍْع الأقشاص ٗفق اىرظـٌٍَ اىرعشٌثً، عِ طشٌق اىضـــــغط اىَثاشـش تْسة ٍرساٌٗح ىنو ٍِ اىذٗاء ٗ 
، ٗ اىرآمو ،لاتح ، اىرفرٍد، اٍرظاص اىَاءـاىض :اخاسـخرةلا حٍس ذٌ اخضاع الأقشاص اىَْرـعح اىث٘ىٍَش،
   .اّرشاس اىَادج اىَعاىعح ٍِ الأقشاص
 
 النتائج
عاىً  اىث٘ىٍَش ضعٍفح اىزٗتاُ فً اىَاء، فإُ ىَادج اىَعاىعحذشٍش ّرائط ٕزا اىثحس اىى أّٔ ٗتاىْسثح ه
تاىث٘ىٍَش ضعٍف ٍقاسّح  ىيَاء، اٍرظاص اىقشص عيى صٌادج فعاه ٍاء ىٔ ذؤشٍشهالإٍرظاص ه
ىقشص ٗطشٌقح طلاتح ا عيى فعالا ذؤشٍشًاأظٖش  اىث٘ىٍَش لاخرلاف فً ٍظذسا فإُمزىل . الإٍرظاص
 اىث٘ىٍَشاخ ُفإاضافح اىى رىل،  .فً اىَاء ىزٗتاُا اىَادج اىَعاىعح سشٌعح ٗ ضعٍفحٍِ  موه ٓ،اىذٗاء ٍِاّرشاس
الأقشاص اىَادج اىَعاىعح ٍِ ٗاّرشاسرٗتاٍّح  عَيٍح اىرحنٌ فًفً أمصش مفاءجاظٖشخ  ىيَاء ٍرظاصعاىٍح الا
 .ىَاءاخ قيٍيح الاٍرظاص هاىث٘ىٍَشٍقاسّح ب
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1. Introduction and Literature Review 
 
It has been estimated that solid-dosage forms constitute about 80% of all dosage 
forms used to provide systemic administration of therapeutic agents. This 
highlights the importance of these dosage forms in the treatment and management 
of disease states. The widespread use of tablets has been achieved as a result of 
their convenience and also the diversity of tablet types. 
 
1.1. Types of Tablets 
Based on the required target of action, stability of the loaded drug, patient 
acceptability, compliance and others, a variety of tablet types does exist and many 
methods can be used to categorize tablets.  
 
1.1.1. Conventional Tablets 
These tablets are designed to provide rapid disintegration and hence rapid drug 
release, and represent a significant proportion of tablets that are clinically used.  
The manufacture of these tablets involves the compression of granules or powders 
(both containing drug) into the required geometry. Following ingestion, the tablets 
will disintegrate within the gastrointestinal tract (stomach), allowing the drug to 
dissolve in the gastric fluid and, ultimately, be absorbed systemically. (1) 
 
1.1.2. Multiple Compressed Tablets 
These are tablets that are composed of more than one layer. Typically there are two 
designs of multiple compressed tablets, multiple-layered and compression coated. 
In the former design the first layer is formed by a relatively light compression of 
the drug containing powder mix/granules. The next layer is then formed by 
compression of the powder/granule mix (containing drug) on top of the lightly 
compressed first layer. Additional layers are formed in a similar fashion. In the 
second approach the initial layer is prepared by light compression (as described 
above), removed and located in a second tablet press. The granules/powders of the 
second coat are fed into the press and allowed to form a constant mass around the 
surface (and edges) of the pressed tablet prior to compression to form the finished 
product. It is, of course, possible to prepare tablets containing more than two layers 
although, in so doing, the complexity of the manufacturing process is dramatically 
increased. (1)  
 
1.1.3. Enteric Coated Tablets 
These are tablets that are coated with a polymer that does not dissolve under acidic 
conditions (i.e. the stomach) but does dissolve under the more alkaline conditions 
of the small intestine (i.e. pH > 4). Enteric polymers are primarily employed as 
coatings of conventional tablet dosage forms and, by inhibiting the dissolution of 
the therapeutic agent within the stomach, offer protection against possible drug 
degradation (e.g. erythromycin)  or irritation of the gastric mucosa (e.g. non-
steroidal anti-inflammatory drugs). Following dissolution of the coating, the tablet 
will disintegrate and the drug will dissolve in the intestinal fluids (thereby 
facilitating absorption). This type of tablet is one of the delayed release dosage 
form. (1, 2) 
Among polymers that are used for enteric coatings are cellulose acetate phthalate, 
cellulose acetate butyrate, Hydroxypropylmethyl cellulose succinate and 
Methacrylic acid co-polymers (Eudragit®). (3) 
 
 
1.1.4. Sugar Coated Tablets 
These are conventional tablets that have been coated with a concentrated sugar 
solution to improve the appearance of the formulation and/or to mask the bitter 
taste of the therapeutic agent. The use of sugar coatings has dramatically decreased 
due to the advent of film-coated tablets (as a result of the improved mechanical 
properties of the latter coating). (1)  
The coating may cover a bitter substance, conceal an unpleasant or mottled 
appearance, or provide a barrier for a substance irritating to the stomach or one 
inactivated by gastric juice. While sugar coating a tablet may increase its weight by 
50 to 100% of the core weight, the compression-coated tablet requires a coating 
that is about twice the weight of the core. If the cores are composed mainly of 
materials of low bulk density, such as fats and waxes, the amount of coating (by 
weight) must be even greater to assure a uniform volume of material surrounding 
the core. (4) 
 
 
1.1.5. Film Coated Tablets 
These are conventional tablets that have been coated with a polymer or a mixture 
of polymers (and, when required, a plasticizer to render the coating flexible). Film 
coatings show improved mechanical properties when compared to sugar coatings 
and, furthermore, film coatings may be deposited over embossed markings on the 
tablet surface. Film coatings are generally less elegant than sugar coatings. (1) 
Examples of polymers that are used to film-coat tablets (and which dissolve in the 
stomach to enable tablet disintegration and drug dissolution) include; 
hydroxypropylmethylcelluose and Eudragit E100 (a co-polymer of 
butylmethacrylate, 2 dimethyl aminoethylmethacrylate and methylmethacrylate, 
1:2:1). (1) 
In addition to improving the appearance of conventional tablets, film coatings are 
employed to control the rate and duration of drug release or to target drug release 
to certain regions of the gastrointestinal tract, e.g. the colon. If the film coating is 
insoluble, the tablet will retain its shape during transit along the gastrointestinal 
tract. Drug release occurs by diffusion through the insoluble coating and 
subsequent partitioning into the gastrointestinal fluids. Examples for such class of 
polymers include ethylcellulose and methacrylate co-polymers (Eudragit
®
 S & L). 
The use of film coatings to target drug release within the gastrointestinal tract 
requires the use of polymers that dissolve within certain pH ranges. For example, 
enteric coatings offer drug targeting to regions of the gastrointestinal tract in which 
the pH is greater than 5.5 (e.g. Eudragit L-100). Targeting drug release to the colon 
involves the use of polymer coatings that dissolve at higher pH values (> 7), e.g. 
Eudragit S-100. (1, 5) 
 
1.1.6. Chewable Tablets 
As indicated by the name, these tablets are chewed within the buccal cavity prior to 
swallowing. The main target applications for this dosage form are administration to 
children and adults who have difficulty in swallowing conventional tablets and 
antacid formulations in which the size of the tablet is normally large and the 
neutralization efficacy of the tablet is related to particle size within the stomach. 
Conversely, chewable tablets are not conventionally used if the drug has issues 
regarding taste acceptability. (1) 
 
 
1.1.7. Effervescent Tablets 
Effervescent tablets are added to aqueous solutions where they will rapidly 
disintegrate and produce either a drug suspension or an aqueous solution. The 
disintegration of the tablet is due to chemical interaction that occurs between two 
components, namely, an organic acid (e.g. citric acid) and sodium bicarbonate in 
the presence of water. The evolution of carbon dioxide from this reaction results in 
tablet disintegration. The patient then consumes the solution/suspension. The main 
advantage of the use of effervescent tablets is the production of a dosage form 
from which the therapeutic agent is more rapidly absorbed than from alternative 
solid-dosage forms (e.g. conventional tablets). (1) 
Conversely, the main disadvantages of this type of dosage form are the possible 
unavailability of water and the need to package these tablets in moisture-
impermeable packaging (typically aluminium foil), to inhibit the interaction 
between the acid and sodium bicarbonate due to the presence of environmental 
moisture. (1) 
 
1.1.8. Buccal and Sublingual Tablets 
Buccal and sublingual tablets are dosage forms that are held within the oral cavity 
and slowly dissolve; the drug is absorbed across the buccal mucosa to produce a 
systemic effect. The type of tablet dictates the location within the oral cavity. 
Accordingly buccal tablets are positioned between the cheek and the gingiva 
whereas sublingual tablets are positioned underneath the tongue. These tablets are 
employed to achieve either rapid absorption into the systemic circulation (e.g. 
glyceryl trinitrate sublingual tablets) or, alternatively, to enable systemic drug 
absorption in situations where oral drug delivery is inappropriate, e.g. nausea. Drug 
absorption across the buccal mucosa avoids first-pass metabolism. Typically 
buccal and sublingual tablets should be formulated to dissolve slowly in vivo (and 
not disintegrate) and to be retained at the site of application and should not contain 
components that stimulate the production of saliva. (1) 
1.1.9. Vaginal Tablets 
These are ovoid-shaped tablets that are inserted into the vagina (using a special 
inserter). Following insertion, retention and slow dissolution of the tablet occur, 
releasing the therapeutic agent to provide the local pharmacological effect (e.g. for 
the treatment of bacterial or fungal infection). Vaginal tablets may also be used to 
provide systemic absorption of therapeutic agents. In a similar fashion to 
buccal/sublingual tablets, it is important that dissolution, and not disintegration, of 
the tablet occurs in vivo, as disintegration will reduce tablet retention within the 
vagina. (1) 
 
 
1.2. Manufacture of Tablets 
In general, there are four main methods for tablet manufacturing. These are wet 
granulation, dry granulation, direct compression (6) and roller compaction 
(chilsonisation) (1). The choice of manufacturing process employed is dependent on 
several factors, including the compression properties of the therapeutic agent, the 
particle size of the therapeutic agent and excipients and the chemical stability of 
the therapeutic agent during the manufacturing process.(1) 
There are four steps which start with mixing of the therapeutic agents with the 
excipients followed by granulation of the mixed powders (this step is excluded in 
case of direct compression). The third step is mixing of the powders or granules 
with other excipients (most   notably lubricants) and finally compression into 
tablets. However, the details of each of these steps will vary depending on the 
manufacturing method used. (1) 
 
 
1.3. Pharmaceutical Polymers 
Polymers are substances of high molecular weight made up of repeating monomer 
units. When all the monomer units are identical, the polymers are referred to as 
homopolymers. Examples include polystyrene, polyethylene, poly (vinyl alcohol) 
and polyvinylpyrrolidone. There may also be homopolymers with much smaller 
chains (oligomers). The different monomers can be arranged in a linear chain in 
either a random manner or in an alternating pattern along the chain. (7) 
Polymer chains can be linear (forming random coils in solution) or branched. 
There may be cross-linking between chains to form three-dimensional networks. 
Highly branched polymers (dendrimers) built around a central core can be 
synthesised with a range of sizes depending on the generation of the dendrimer. 
Moreover, polymers do not form perfect crystals but have crystalline regions 
surrounded by amorphous regions. (7) 
 
1.3.1. Types of Pharmaceutical Polymers 
Owing to their aqueous solubility, polymers can be categorized into two classes, 
water soluble (hydrophilic) and water insoluble (hydrophobic) polymers. 
Hydrophilic polymers are widely utilized in pharmacy as suspending agents, 
emulsifiers, binding agents in tablets, thickeners of liquid dosage forms and in film 
coating of tablets. On the other hand, hydrophobic polymers are mainly used in 
packaging material and tubing, and in the fabrication of membranes and films. 
Important properties of hydrophobic polymers which affect their suitability for use 
in pharmacy are their permeability to drugs and gases and their tendency to adsorb 
drugs. (7) 
 
 
 
1.3.2. Properties of Pharmaceutical Polymers 
Pharmaceutical polymers are characterized by different properties that organize 
their selection and suitability for application in pharmaceutical technology. (7) 
The wide range of physicochemical properties offered by these materials may be 
utilized to improve both the clinical and nonclinical, (e.g., manufacturing, 
stability), properties of dosage forms. (3) 
 
1.3.2.1. Bioadhesion 
Bioadhesion arises from interactions between the polymer chains and the 
macromolecules on the mucosal surface based on the acquired charges on the 
surface of the molecules. This property is critical when selecting polymer for 
bioadhesive tablets that need optimum mucosal adhesion for most favorable 
physical performance of the dosage form. (8)  
 
1.3.2.2. Crystallization and Amorphism 
Defects in the crystals allow preparation of microcrystals, e.g. microcrystalline 
cellulose (Avicel) by disruption of larger crystals. (7) 
Polymers display different thermal, physical, and mechanical properties depending 
on their structure, molecular weight, linearity, intra- and intermolecular 
interactions. If the structure is linear, polymer chains can pack together in regular 
arrays. For example, polypropylene chains fit together in a way that intermolecular 
attractions stabilize the chains into a regular lattice or crystalline state. With 
increased temperature, the crystal cells start to melt and the whole polymer mass 
suddenly melts at a certain temperature. Above the melting temperature, polymer 
molecules are in continuous motion and the molecules can slip past one another. In 
many cases, the structure of a polymer is so irregular that crystal formation is 
thermodynamically infeasible. Such polymers form glass instead of crystal 
domains. A glass is a solid material existing in a noncrystalline (i.e., amorphous) 
state. Amorphous structure is formed due to either rapid cooling of a polymer melt 
in which crystallization is prevented by quenching or due to the lack of structural 
regularity in the polymer structure. Rotation around single bonds of the polymer 
chains becomes very difficult at low temperatures during rapid cooling; therefore, 
the polymer molecules forcedly adopt a disordered state and form an amorphous 
structure. Amorphous or glassy polymers do not generally display a sharp melting 
point; instead, they soften over a wide temperature range. (9) 
 
1.3.2.3. Degree of Chain Substitution 
It‘s the average number of hydroxyl group (%) substituted. e.g. by ester or ether 
groups, per monosaccharide unit in a polysaccharide. usually referring to cellulose. 
The properties of any of the many useful cellulose derivatives depend not only on 
the particular derivative but also on the degree of substitution which may vary 
from zero to three. The maximum value obtainable can be limited by steric 
crowding around the pyranose ring or by accessibility. (10) 
Generally, this property is very useful in synthesis of polymers with specific 
physicochemical or rheological properties to serve in special types of 
manufacturing. 
 
1.3.2.4. Viscosity 
Viscosity is a measure of the resistance of a fluid which is being deformed by 
either shear stress or tensile stress. It describes a fluid's internal resistance to flow. 
(Wikipedia.org) 
Viscosity of a polymer solution depends on concentration and size (i.e., molecular 
weight) of the dissolved polymer. By measuring the solution viscosity we should 
be able to get an idea about molecular weight. 
Water-soluble hydrophilic polymer (e.g. HPMC), can affect the dissolution 
behavior and transport properties of drug molecules by an increase in solution 
viscosity. There has been considerable interest in the relationship between bulk 
solution viscosity and the rate of dissolution of a wide range of materials. A 
number of empirical equations have been proposed to describe the relationship of 
dissolution rate as a function of the viscosity of the dissolution medium. Generally, 
this type of polymers (hydrophilic) absorbs water to swell and form a gel. This gel 
serves as a barrier to drug diffusion. The controlled release behavior or the loaded 
drug is obtained from high viscosity of gel layer. (11) 
So, the viscosity grade of the polymer affects the release of the drug from matrix 
system and also inhibits the crystallization of the drug by increasing the viscosity 
of crystallization medium. 
 
1.3.2.5. Gel strength 
The primary rate-controlling ingredients of a hydrophilic matrix are polymers that 
would swell on contact with the aqueous solution and form a gel layer on the 
surface of the system. Robust swelling/gelling properties and straightforward 
manufacturing processes are to a large degree responsible for the versatility and 
performance of the system. The gel layer has been identified as the rate-controlling 
mechanisms. (12) 
Generally, there are three layers, the dry core surrounded by glassy layer, then gel 
layer and finally the diffusion layer. However, gel strength within the dosage form 
can be compromised when polymers of low molecular weight are used. (12) 
Recently, a self correcting HPMC-based matrix having strong gels was developed 
and showed insensitivity to both pH and stirring condition. (13, 14) 
 
 
1.3.2.6. Swelling and erosion 
Polymer swelling is a hydration or water uptake and the Erosion can be described 
as polymer dissolution or the disentanglement of polymer chains from the gel 
surface and transfer of the polymer to the bulk solution. Erosion can be used as 
disintegrant when designing a delivery system for insoluble drugs. Here, erosion is 
the main mechanism facilitating transfer of the insoluble drug out of the tablet 
matrix and into the dissolution medium. However, poor release characteristics such 
as variable burst release and dose dumping may be expected for a highly soluble 
drug that is formulated in a highly erodible dosage form. (15) 
Hydrophilic matrices are widely used to develop oral sustained release 
formulations. They can be used for controlled release of both water soluble and 
insoluble drugs. The release of drugs varies with the nature of the matrix and also 
with the complex interaction of swelling, diffusion and erosion process. (16) 
The swelling controlled release systems consist of a drug molecularly dissolved or 
dispersed at high concentration in a polymer matrix. If the drug has a limited 
solubility in the swollen polymer matrix, it is probable that an undissolved drug 
front will be observed within the continuously swelling polymer gel layer. (17)  
In addition, Peppas indicated that in swellable matrix tablets, drug dissolution 
might be responsible for an observed zero-order release mechanism. (18)  
On the other side, swelling and erosion behaviors and drug solubility control the 
release kinetic of matrix system. Depending on drug solubility, three fronts can be 
observed; swelling front, diffusion front and erosion front. In the last front there is 
an identifying boundary between matrix and dissolution medium. (19) 
Generally, there are three cases for the effect of swelling and erosion rates on drug 
release kinetics. The 1
st
 one is that the swelling rate is faster than erosion rate, this 
indicates delayed release kinetics. The 2
nd
 case is that erosion rate is larger than 
swelling rate, and this indicates immediate release kinetics. The 3
rd
 one is that the 
swelling and erosion rates are equal indicating that much of the kinetics depends 
on drug solubility. It‘s a complicated process to indicate the exact relationship 
between swellings, erosion and release kinetics of the drug, because there are many 
other factors influencing this relationship. (3) 
Depending on the properties of the polymer used, drug release from the tablets 
may be swelling-controlled, erosion-controlled, multiple mechanism controlled. 
 
1.3.3. Applications of Polymers in Drug Delivery 
The following sections deals with how deep polymers contribute to the 
pharmaceutical and formulation technology. 
 
1.3.3.1. Film Coating 
Polymer solutions allowed to evaporate produce polymeric films which can act as 
protective layers for tablets or granules containing sensitive drug substances or as a 
rate-controlling barrier to drug release. Film coats have been divided into two 
types: those that dissolve rapidly and those that behave as dialysis membranes 
allowing slow diffusion of solute or some delayed diffusion by acting as gel 
layers.(7)  The application is utilized for enteric, colonic and target drug delivery. 
 
1.3.3.2. Matrix Forming 
Utilization of polymer as matrixing agent for controlled release non conventional 
tablets might be the most interesting application and many relevant reports have 
attributed this utilization to the biocompatibility of these polymers. 
 
1.3.3.2.1. A non-eroding matrix 
The mechanism of sustained release is the passage of drug through pores in the 
matrix if this is made of water-insoluble polymer (hydrophobic matrices), or by 
another way, entry of water into the polymer matrix followed by swelling and 
gelation and then diffusion of drug through the viscous gel when water-soluble 
matrices (hydrophilic matrices) are used. (7) 
 
1.3.3.2.2. An eroding matrix 
Drug is released when the polymer matrix in which a drug is dissolved or dispersed 
erodes by either bulk erosion or surface erosion. (7) 
 
 
1.3.4. HPMC (Hypromellose) 
Hypromellose is cellulose hydroxypropyl methyl ether [9004-65-3]. It‘s an 
odorless and tasteless, white or creamy white fibrous or granular powder. It has 
many synonyms as benecel MHPC; E464; hydroxypropyl methylcellulose; HPMC; 
Methocel; methylcellulose propylene glycol ether; methyl hydroxypropylcellulose; 
Metolose and Tylopur. (20) 
The PhEur 2005 describes hypromellose as a partly Omethylated and O-(2-
hydroxypropylated) cellulose. It is available in several grades that vary in viscosity 
and extent of substitution. Grades may be distinguished by appending a number 
indicative of the apparent viscosity, in mPa s, of a 2% w/w aqueous solution at 
208C. Hypromellose defined in the USP 28 specifies the substitution type by 
appending a four-digit number to the nonproprietary name: e.g., hypromellose 
1828. The first two digits refer to the approximate percentage content of the 
methoxy group (OCH3). The second two digits refer to the approximate percentage 
content of the hydroxypropoxy group (OCH2CH (OH) CH3), calculated on a dried 
basis. Molecular weight is approximately 10000-1500000 Da. The JP 2001 
includes three separate monographs for hypromellose: HPMC 2208, 2906, and 
2910, respectively. (20) 
The polymer has been extensively used as coating agent, film-former, rate-
controlling polymer for sustained release, stabilizing agent, suspending agent, 
tablet binder and viscosity-increasing agent. (20) 
Hypromellose has many applications in pharmaceutical formulation or technology 
as widely used in oral, ophthalmic and topical pharmaceutical formulations. 
In oral products, hypromellose is primarily used as a tablet binder, (21) in film-
coating, (22) and as a matrix for use in extended-release tablet formulations. 
Concentrations between 2% and 5% w/w may be used as a binder in either wet- or 
dry-granulation processes. High-viscosity grades may be used to retard the release 
of drugs from a matrix at levels of 10–80% w/w in tablets and capsules. Depending 
upon the viscosity grade, concentrations of 2–20% w/w are used for film-forming 
solutions to film-coat tablets. Lower-viscosity grades are used in aqueous film-
coating solutions, while higher viscosity grades are used with organic solvents. 
Examples of film-coating materials that are commercially available include 
AnyCoat C, Spectracel, and Pharmacoat. Hypromellose is also used as a 
suspending and thickening agent in topical formulations. Compared with 
methylcellulose, hypromellose produces aqueous solutions of greater clarity, with 
fewer undispersed fibers present, and is therefore preferred in formulations for 
ophthalmic use. Hypromellose at concentrations between 0.45–1.0% w/w may be 
added as a thickening agent to vehicles for eye drops and artificial tear solutions. 
Hypromellose is also used as an emulsifier, suspending agent, and stabilizing agent 
in topical gels and ointments. As a protective colloid, it can prevent droplets and 
particles from coalescing or agglomerating, thus inhibiting the formation of 
sediments. In addition, hypromellose is used in the manufacture of capsules, as an 
adhesive in plastic bandages, and as a wetting agent for hard contact lenses. It is 
also widely used in cosmetics and food products. (20) 
 
1.3.5. PVP (Povidone) 
Povidone is 1-Ethenyl-2-pyrrolidinone homopolymer [9003-39-8]. It occurs as a 
fine, white to creamy-white colored, odorless or almost odorless, hygroscopic 
powder. It has many synonyms as   E1201; Kollidon; Plasdone; poly [1-(2-oxo-1-
pyrrolidinyl) ethylene]; polyvidone; polyvinylpyrrolidone; PVP; 1-vinyl-2-
pyrrolidinone polymer. (23) 
The polymer has extensively been used as disintegrant, dissolution aid, suspending 
agent and tablet binder. (23)  
Although povidone is used in a variety of pharmaceutical formulations, it is 
primarily used in solid-dosage forms. In tableting, povidone solutions are used as 
binders in wet granulation processes. (24, 25) Povidone is also added to powder 
blends in the dry form and granulated in situ by the addition of water, alcohol, or 
hydroalcoholic solutions. Povidone is used as a solubilizer in oral and parenteral 
formulations and has been shown to enhance dissolution of poorly soluble drugs 
from solid-dosage forms. (26-28) Povidone solutions may also be used as coating 
agents. Povidone is additionally used as a suspending, stabilizing, or viscosity-
increasing agent in a number of topical and oral suspensions and solutions. The 
solubility of a number of poorly soluble active drugs may be increased by mixing 
with povidone. (23) 
   
 
 
1.3.6. Factors affecting drug release from matrix tablets 
A matrix system consists of active and inactive ingredients that are homogeneously 
mixed in the dosage form. It is the most commonly used oral controlled release 
technology. 
There are many factors affecting drug release from matrix systems. The most 
effective one is the Type and the solubility of the polymer present inside the matrix 
system to form either hydrophobic or Hydrophilic matrix system. The hydrophobic 
is the only system where use of a polymer is not essential to provide controlled 
drug release, although insoluble polymers have been used. To modulate drug 
release of this system, it may be necessary to incorporate soluble ingredients such 
as lactose into the formulation. The hydrophilic system contains polymers that 
would swell on contact with the aqueous solution and form a gel layer on the 
surface of the system, which would be responsible for release rate of the drug. (12) 
The source is one of the factors that affect the release kinetic by which content %, 
fineness, degree of substitution and water content vary from one source to another 
and so influencing the physical properties that affect the controlled release rate 
and/or kinetic of the loaded drug. 
Viscosity grade of polymer is also an effective factor in drug release rate. In which 
the viscosity grade is controlling the release mechanism and the physiochemical 
performance of the gel layer (Gel Strength). Also the erosion and swelling % are 
affected by viscosity grade of the polymer.  
The solubility of the loaded drug also interferes with polymers fitted inside the 
matrix system to either increase or decreases the rate of dissolution and diffusion 
of the drug to dissolution medium.  
   
 
1.4. Controlled release oral dosage forms  
The development of controlled-release formulations continues to be a big success 
for the pharmaceutical industry. The success of any technology relies on the ease 
of its manufacturing process and its reproducibility of desirable biopharmaceutical 
properties. The technologies behind oral drug delivery have emerged from the 
mainstream pharmaceutical industry and have become influential forces in their 
own right, as evidenced by the burgeoning ―drug delivery companies‖ that are at 
the forefront of innovation and hold their own niche market. Drug delivery 
companies and their pharmaceutical industry partners are poised to reap the 
rewards of the multibillion-dollar drug delivery market, which has grown to about 
$70 billion by 2005. (29) 
Benefit behind utilization of oral controlled release drug delivery systems are 
numerous and include (but not limited to) less fluctuation in blood drug 
concentration, reduction in adverse drug side effects, improvement in tolerability 
(30), enhancement of patient compliance and reduction of healthcare cost (31).  
 
1.4.1. Currently utilized oral controlled release systems 
Advances in oral controlled-release technology are attributed to the development 
of novel biocompatible polymers and machineries that allow preparation of novel 
design dosage forms in a reproducible manner. The main oral drug-delivery 
approaches that have survived through the ages are coating technology using 
various polymers for coating tablets, matrix systems made of swellable or 
nonswellable polymers, slowly eroding devices and osmotically controlled devices. 
Conventional tablet formulations are still popular in the design of single-unit, 
matrix-type controlled release dosage forms. The advancement of granulation 
technology and the array of polymers available with various physicochemical 
properties (such as modified cellulose or starch derivatives) have made the 
development of novel oral controlled release systems possible. (29) 
Matrix devices made with cellulose or acrylic acid derivatives, which release the 
homogeneously dispersed drug based on the penetration of water through the 
matrix, have gained steady popularity because of their simplicity in design. The 
drawback of matrix-type delivery systems is their first-order drug delivery 
mechanism caused by changing surface area and drug diffusional path length with 
time. This drawback has been addressed by osmotic delivery systems, which 
maintain a zero-order drug release irrespective of the pH and hydrodynamics of the 
GI tract. Multiparticulate systems are gaining favor over single-unit dosage forms 
because of their desirable distribution characteristics, reproducible transit time, and 
reduced chance of gastric irritation owing to the localization of drug delivery. (29) 
Although several technologies for the production of microparticulate systems have 
been designed, thus far the mainstream technologies are still based on spray-
drying, spheronization, and film-coating technology. (29) 
 
1.5. Design of Experiment (DOE) 
Experimentation is carried out to determine the relationship (usually in the form of 
a mathematical model) between factors acting on the system and the response or 
properties of the system (the system being a process or a product, or both). The 
information is then used to achieve, or to further, the aims of the project. So, the 
experimental design (DOE) can be defined as the strategy for setting up 
experiments in such a manner that the information required is obtained as 
efficiently and precisely as possible. (32) 
 
1.5.1. Full factorial designs in two levels 
A design in which every setting of every factor appears with every setting of every 
other factor is a full factorial design. A common experimental design is one with 
all input factors set at two levels each. These levels are called ‗high‘ and ‗low‘ or 
‗+1‘ and ‗-1‘, respectively. A design with all possible high/low combinations of all 
the input factors is called a full factorial design in two levels. If there are k factors, 
each at 2 levels, a full factorial design has 2
k
 runs. 
Full factorial designs not recommended for 5 or more factors. When the number of 
factors is 5 or greater, a full factorial design requires a large number of runs and is 
not very efficient, the fractional factorial design or a Plackett-Burman design a 
better choice for 5 or more factors. (33)  
 
1.6. Chlorpheniramine Maleate 
It is one of  H1-receptor antagonist that has antihistaminic action. The powder is 
white or almost white, crystalline form which is freely soluble in water and 
ethanol. (BP, 2007) 
Based on the water solubility behavior and simplified assay method (U. V. 
spectrophotometric analysis), the drug is selected as a model drug in this project. 
 
1.7. Atenolol 
Atenolol is beta-adrenoceptor antagonist acts as hypotensive agent. It‘s white or 
almost white powder, sparingly soluble in water, soluble in ethanol, slightly 
soluble in methylene chloride. (BP 2007) 
Based on the water insolubility behavior and simplified assay method (U. V. 
spectrophotometric analysis), the drug is selected as a model drug in this project. 
 1.8. Similarity factor (f₂) 
FDA has placed more emphasis on a dissolution profile comparison in the area of 
post-approval changes and biowaivers. Under appropriate test conditions, a 
dissolution profile can characterize the product more precisely than a single point 
dissolution test. A dissolution profile comparison between pre-change and post-
change products for SUPAC (Supplemental Post Approval Changes) related 
changes, or with different strengths, helps assure similarity in product performance 
and signals bioinequivalence. (34) 
Among several methods investigated for dissolution profile comparison, f₂ is the 
simplest. Moore and Flanner proposed an independent mathematical model 
approach to compare the dissolution profile using two factors, f1 and f₂. (35) 
 
 
 
Where Rt and Tt are the cumulative percentage dissolved at each of the selected n 
time points of the reference and test product respectively. The factor f1 is 
proportional to the average difference between the two profiles, whereas factor f₂ is 
inversely proportional to the average squared difference between the two profiles, 
with emphasis on the larger difference among all the time-points. The factor f₂ 
measures the closeness between the two profiles. Because of the nature of 
measurement, f1 was described as difference factor, and f₂ as similarity factor. In 
dissolution profile comparisons, especially to assure similarity in product 
performance, regulatory interest is in knowing how similar the two curves are, and 
to have a measure which is more sensitive to large differences at any particular 
time point. For this reason, the f₂ comparison has been the focus in Agency 
guidance. When the two profiles are identical, f₂=100. An average difference of 
10% at all measured time-points results in an f₂ value of 50. FDA has set a public 
standard of f₂ value (between 50 and 100) to indicate similarity between two 
dissolution profiles. (34, 35) 
Scope of the Work 
 
Generally, the objective of this project is to study the effect of the some 
formulation variables on the physical performance of oral matrix tablets. This is by 
applying 2³ full factorial design in order to study the impact of three factors on the 
drug release from matrix system. Specifically, these factors are the supplier source 
of the polymers, solubility of the polymers and solubility of the loaded drugs. 
Moreover, the study is designed in away to permit the analysis of the influences 
these factors might have on the drug release rate and drug release kinetics. 
 
 
 
 
 
 
 
 
 
 
 
2. Materials and Methods 
 
2.1. Materials 
The following materials have been utilized during the experimental part of the 
research:  
HPMC (K4M 4000 cps, pharmaceutical grade) was obtained from two different 
sources. One is a product of Bulk Medicines & Pharmaceuticals (Germany), and 
the other is a product of Taian Ruitai Cellulose Co., Ltd ―Alcapharm‖ (China). In 
both sources, the polymer is used as received.  
PVP (K-30, pharmaceutical grade) was obtained also from two different sources. 
One is the product of Bulk Medicines & Pharmaceuticals (Germany) and has been 
donated by Amipharma Laboratories Ltd. (Sudan) and the other is a product of 
Nanfang Industrial Co., Ltd. (China) and was donated by Citypharm 
Pharmaceutical IND. (Sudan). 
Mg stearate is a product of Huzhou Zhanwang Pharmaceutical Co., Ltd. (China) 
and donated by Shanghai-Sudan Pharmaceutical Co., Ltd. (Sudan). 
Model drugs used in this study (Chlorpheniramine Maleate and Atenolol) were 
pharmaceutical grade products of Supriya Chemicals Pvt. Ltd and Ipca 
Laboratories Ltd (Mumbai, India), respectively and were received as a gift from 
Amipharma Laboratories Ltd. (Sudan). 
Other materials and reagents were analytical grade obtained from different 
commercial sources. 
 
2.2. Instruments and Apparatus 
The following instruments were used in the experimental part of the research: 
Single Punch Tablet Compression Machine (Cadmach®, Ahmedbad-8, India); 
Analytical Balance (Sartorius®, AG CP 124S, Germany); Tablet Friability Tester 
(ERWEKA® TA, Germany); Tablet Hardness Tester (ERWEKA® Gmbh, 
Hensenstamm, Germany); Tablet Dissolution Tester (ERWEKA®, Germany); 
U.V. Spectrophotometer (double beam UV-1800, Shimadzu, Japan).  
 
 
2.3. Methods 
2.3.1. Experimental Design: 
Based on the aim and the data of this project,  full factorial was selected as an 
experimental design, in which 3 factors were examined at two levels (two sources 
of HPMC 4000 cps, two sources of PVP-30 and two different solubility profiles‘ 
drugs. The design composed of 8 experimental runs and the layout is shown in 
Table I 
 
 
 
 
 
  
Table I 
Experimental runs layout for the 2
3
 design 
 
 
 
 
Source of HPMC
a 
 
 
Source of PVP
a 
 
Drug solubility
b 
Run 1 [+1] [+1] [+1] 
Run 2 [-1] [+1] [+1] 
Run 3 [+1] [-1] [+1] 
Run 4 [-1] [-1] [+1] 
Run 5 [+1] [+1] [-1] 
Run 6 [-1] [+1] [-1] 
Run 7 [+1] [-1] [-1] 
Run 8 [-1] [-1] [-1] 
a
 -1 and +1 stand for Germany and China, respectively; 
b
 -1 and +1 stand for water soluble and water insoluble, 
respectively.  
 
2.3.2. Preparation of Tablets 
For all runs, the drug: polymer ratio is kept 1:1 similarly to HPMC: PVP ratio, with 
mg stearate content (as a lubricant) fixed as 1% w/w. For each formulation run, the 
constituents of 100 tablets were mixed separately using mortar and pestle for 10 
minutes, lubricated and compressed into tablets using single punch tableting 
machine equipped with size 9 mm flat punch. The cleaning of the machine is 
carried out after preparation of each formulation run using ethanol. Each 
formulation run is packaged in tightly closed glass bottle, and then labeled with the 
number of the run. Produced tablets are weighed and have an average of 202mg 
containing 100mg of loaded drug per unit dosage. 
 
 
2.3.3. Friability Test 
Tablets within all runs were subjected to friability testing (USP, 2010) where 10 
tablets from each produced tablets batch were weighed and introduced in the right 
drum of tablet friability tester and same number in the left drum. The device was 
turned on at 25 r/min speed for 4 minutes and the dust is removed after test. The 
tablets were weighed after test and the friability was calculated using the average 
% loss from the two drums. 
 
2.3.4. Hardness Test 
10 tablets from each formulation runs were placed in hardness tester. The device 
measures hardness in N (Newton) and diameter in mm. The measured values and 
statistics of these values were calculated and recorded automatically by computer 
program connected to the device.  
 
2.3.5. Swelling and Erosion Tests 
Tablets sample from each formulation run were investigated for swelling and 
erosion performance in order to correlate the observed drug release phenomena 
with the rates of polymer hydration, swelling and erosion. Weighed tablets were 
placed in the beaker of 100 ml distilled water. After 0.25, 0.5, 0.75, 1, 2, 3, 4 and 5 
h, each tablet is removed from beaker using spatula, blotted to remove excess 
water and weighed on an analytical balance. The wet tablet were then dried in an 
oven at 50 °C for 24 h, allowed to cool and finally weighed until constant weight 
was achieved (final dry weight). The experiment was performed in triplicate for 
each time point and fresh samples were used for each individual time point. The 
increase in weight due to absorbed liquid (Q) was estimated at each time point 
from the following equation: 
 
        
 
Where  is the mass of the hydrated sample before drying and  the final 
weight of the same dried and partially eroded sample. The percentage erosion (E) 
was estimated from the following equation: 
 
 
 
Where  is the initial dry sample weight. 
 
 
2.3.6. Dissolution Test 
The dissolution test was carried out using apparatus 1 (Basket apparatus) (USP 
2010) set at 100 r/min and complete sink condition. In order to reproduce the 
digestive physiological phases, 1000 ml samples of dissolution medium were used 
at 37 ± 0.5°C. 0.1 N HCl (pH 1.2) was used as dissolution medium and 6 tablets 
from each batch were subjected to the test. Dissolution samples were withdrawn at 
predetermined time points, filtered and analyzed spectrophotometrically at 275 and 
265nm for Atenolol and Chlorpheniramine Maleate, respectively, considering 
sample taken at zero time as a blank sample. The mean cumulative percentage of 
drug was calculated and plotted against time.  
 
2.3.6.1. Drug Release Kinetics:  
Data derived from dissolution test were subjected to model fitting and statistical 
analysis in order to explore the kinetics of the drug release. The model selected 
was Korsmeyer and Peppas equation where dissolution data <60% drug release 
were fitted to the model and the fitting process aided by the software PCP Disso 
V3 (36) in order to determine the diffusional exponent (n) that is used to 
characterize the drug transport mechanism. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Result 
 
3.1. Friability Test 
Table II shows average friability of tablet formulation runs in the experimental 
design and the result indicated that all of tablet formulations investigated were 
within the acceptable pharmacoepial limit of friability (less than 1%, BP 2010). 
 
Table II 
The Friability Test Result of Tablet Formulation runs in the Factorial Design 
Formulation Run Average Friability (%) Drug 
Run 1 0.12 Atenolol 
Run 2 0.02 Atenolol 
Run 3 0.05 Atenolol 
Run 4 0.17 Atenolol 
Run 5 0.20 Chlorpheniramine Maleate 
Run 6 0.35 Chlorpheniramine Maleate 
Run 7 0.05 Chlorpheniramine Maleate 
Run 8 0.05 Chlorpheniramine Maleate 
 
 
3.2. Hardness Test 
Average hardness of tablet formulations in the factorial design are shown in figure 
1 and it is apparent that all formulations investigated have met the pharmacoepial 
criteria for uncoated tablet where the accepted hardness range is considered as 39-
98 N (BP, 1998) 
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Formulation Runs (1-4) and (5-6) represent Atenolol and Chlorpheniramine Maleate respectively.  
Fig. 1 
Average tablet hardness of formulation runs in the experimental design. Each value is the 
average of 10 determinations with error bars indicating values of standard deviations. 
 
3.3. Swelling and Erosion Tests 
For formulation runs 5, 6, 7 and 8 which are specified to load soluble drug 
(Chlorpheniramine Maleate), the tablets immediately start to form gelatinous 
substratum foundation after 15 – 20 minutes upon immersion in distilled water. So 
the test was not continued for these formulation runs.  
Figure 2 illustrates the swelling behaviors of tablets within formulation runs 1-4 
that loaded with the insoluble drug Atenolol.  
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Fig. 2 
Swelling profile of tablet within formulation runs 1-4 loaded with Atenolol.  
 
 
 
Fig. 3 
Erosion profile of tablet within formulation runs 1-4 loaded with Atenolol.  
3.4. Dissolution Test 
Following the procedure described in the methods section, the data obtained as 
measures from U.V. spectrophotometric device for dissolution samples were 
arranged in tables and analyzed by PCP Disso V3 (36) computer software program 
to calculate the diffusional exponent (n) and rate constant (k) that characterize drug 
release process. The data analyzed are those corresponding to less than 60% 
release and graphs of release profile were thus generated.   
 
 
3.4.1. Standard calibration curves of Atenolol and Chlorpheneramine maleate 
in 0.1 N HCl 
Figure 4 shows the plot of atenolol different concentrations (g/ml) and their 
respective UV absorbance at 275 nm (BP, 2007). A linear correlation between 
atenolol concentration and absorbance with high determination coefficient was 
achieved in the concentration range of 10—500 g/ml (R2 =1).  
 Fig. 4 
Calibration curve of Atenolol in 0.1 N HCl 
 
For chlorpheneramine maleate, Figure 5 shows the plot of chlorpheniramine 
maleate different concentrations (g/ml) and their respective UV absorbance at 
265 nm (BP 2007). There is a linear correlation between chlorpheniramine maleate 
concentration ranged 1-100 g/ml and absorbance with high determination 
coefficient (R
2
 = 1). 
 
 Fig. 5 
Calibration curve of Chlorpheniramine maleate in 0.1 N HCl 
 
3.4.2. Release Profile of Atenolol  
Atenolol is the insoluble drug module used in the formulation runs 1, 2, 3 and 4. 
Figure 6 revealed Atenolol release % versus time (hr) for formulation run 1, 2, 3 
and 4 respectively.  The release % data taken were less than 60 % where data can 
be effectively utilized to determine values of the diffusional exponent, n and the 
release constant, k. Estimated values for both components of release kinetics and 
the respective determination coefficient are summarized in Table III.    
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Fig. 6  
Release profile of Atenolol from tablet formulation runs 1-4 
 
Table III 
Values of release kinetics components, n and k, for Atenolol and Chlorpheneramine 
maleate from different tablet formulation runs  
Formulation Run N k R
2 
Run 1 0.4920 28.6798 0.9992 
Run 2 0.4956 28.3471 0.9981 
Run 3 0.4979 27.9818 0.9932 
Run 4 0.4997 28.4998 0.9992 
Run 5 0.6965 97.4890 1 
Run 6 0.7030 97.6199 1 
Run 7 0.6498 97.6567 1 
Run 8 0.7388 93.9171 1 
(n) Diffusional exponent; (k) Constant; ( ) Determination Coefficient 
 
 
3.4.3. Release Profile of Chlorpheniramine Maleate  
Chlorpheniramine maleate is the soluble drug model used in the formulation runs 
5, 6, 7 and 8. Figure 7 shows the release pattern of chlorpheniramine maleate (as 
release %) versus time (hr) for formulation runs 5, 6, 7 and 8. Once more, the 
accepted release % data were those less than 60 % and values for release kinetics 
components are summarized in Table III.    
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Fig. 7 
Release profile of Chlorpheniramine maleate from tablet formulation runs 5-8 
 
 
 
 
 
4. Discussion, Conclusion and Recommendation 
 
4.1. Discussion 
4.1.1. The Influence of Swelling and Erosion Percent on Dissolution Behavior 
of Insoluble Drug (Atenolol) 
In order to examine the effects that swelling and erosion rates might have on 
dissolution behavior of insoluble drug (atenolol), a three directional surface plot 
was generated. The data utilized were those associated with 1 hour time interval 
for the three nominated variables as shown in figure 8.  
 
Drug release % = 24.6757+0.1619(swelling)-0.3494 (erosion) 
Fig. 8 
Surface Plot for the effect of Swelling and Erosion on Dissolution Behavior of Insoluble 
Drug (Atenolol) 
The surface plot revealed a proportional relation between drug release and % 
swelling. Moreover, analysis of coefficients of regression equation associated with 
the two variables shown in the figure support the dominance of the inhibitory 
effect of erosion on the drug release compared to the positive one exhibited by the 
swelling, as evident by the magnitude and sign of coefficients associated with the 
two variables. 
The previous discussion shows that the effect of the hydrophilic polymer (HPMC) 
on uptake of water and swelling % is stronger than the effect of hydrophobic 
polymer (PVP). This might explain the increase of percentage drug released owing 
to increase in swelling % as well as the increase in gelling layer causing the drug 
diffusion. Consequently, both hydrophilic and hydrophobic polymers control the 
rate diffusion of the drug from matrix system by swelling and erosion actions. This 
is in agree with the findings of Li., et al, (2006) where authors were able to show 
that the dual release processes make hydrophilic matrices more suitable for 
insoluble molecules than other diffusion-controlled systems.(37). 
Furthermore, the addition of PVP K-30 (hydrophobic) to HPMC (Hydrophilic) 
tablets improved the HPMC matrix structure so as to release the drug in constant 
amounts in each time interval. This has been mentioned in relevant published work 
(Saeio, et al., 2007) where authors attributed such release profile to the enhanced 
swelling-erosion balance of the matrix. (38)   
 
4.1.2. The Influence of Polymers Source on Tablet Hardness of Insoluble Drug 
(Atenolol) 
According to the experimental design (Table I), formulation runs 1, 2, 3 and 4 
contain atenolol as insoluble drug model. These formulation runs contain the same 
type of polymer with the same ratio; 100 mg of atenolol, 100 mg of polymer 
divided into 50 mg HPMC and 50 mg PVP, but with different source.   
 
 
Chi: China source, Ger: Germany, X: Y for HPMC: PVP  
Fig. 9 
The Relationship between Polymers Source and Hardness of Insoluble Drug (Atenolol) 
 
Although the four formulations runs (1-4) have the same content and type of the 
polymers, and compressed under the same loading level, differences in tablets 
hardness were observed. Under such conditions, variation in hardness could 
possibly be attributed to the different source of the polymers (Germany and China). 
Generally, the Germany polymer source results in tablets with lower hardness 
compared to those prepared with Chinese one.  
In fact, this variation could be explained in terms of the differences in percentage 
humidity, purity percent (content %), particle size and viscosity grade that the 
same polymer of different source might have.  
 
4.1.3. The Influence of Polymers Source on Dissolution Behavior of Insoluble 
Drug (Atenolol) 
To determine the possible effects of polymers source on dissolution behavior of 
insoluble drug, a column chart was created using the drug release percent at the 
same time point (6 hours) for all four formulation runs as shown in figure 10. 
 
 Chi: China source, Ger: Germany, X: Y for HPMC: PVP  
Fig. 10 
The Effect of Polymers Source on Dissolution Behavior of Atenolol 
 
Evidenced from the figure that the difference in polymer source affect the drug 
release behavior of atenolol tablet. This effect has been very clear in run number 4 
that revealed 67% drug release at 6 hr time interval compared to the other three run 
which achieved 100% drug release at the same time interval. 
At least under the present experimental condition where other variables kept the 
same, one could conclude that the difference in polymers source might be the 
reason for the revealed variation in atenolol dissolution rate. Once again such 
findings could possibly be explained in terms of the variation in content, humidity 
and particle size that the same polymer might measure when imported from 
different sources.  
Although, the manufacture process of polymer was done in specific and known 
condition. But, the difference in tablet physical performance of the same drug can 
be observed.   
 
 
4.1.4. The Influence of Polymer Source and Hardness on Dissolution Behavior 
of Soluble Drug (Chlorpheniramine Maleate) 
In order to examine the effects that polymer source and hardness might have on 
dissolution behavior of soluble drug (chlorpheniramine maleate), a three 
directional surface plot was generated. The data utilized were those associated with 
1 hour time interval for the three nominated variables as shown in figure 11.  
 
 
 
 
 Drug release % = 17.3701-7.5214(Polymer Source)+0.9193(hardness) 
-1 and +1 stand for Germany and China, respectively. 
 
  Fig. 11 
The effect of Polymer Source and Hardness on Dissolution Behavior of soluble drug 
(Chlorpheniramine Maleate) 
 
The surface plot revealed a proportional relation between German source and drug 
release %, in which the polymer from Germany has more diffusional properties 
than Chinese one. Moreover, analysis of coefficients of regression equation 
associated with the two variables shown in the figure support the dominance of the 
effect of difference in polymer source compared to the tablet hardness effect on 
drug release %, as evident by the magnitude and sign of coefficients associated 
with the two variables. 
The previous discussion shows that the effect of the difference in polymer source is 
stronger than tablet hardness effect. This might explain the increase of percentage 
drug released owing to bias to German source.  
The tablet hardness also has an effect on percentage drug release, which is detected 
by coefficient associated with y axis. 
It has been published that not only the swelling property of the polymer but also its 
hydrophobicity and the hardness of the tablet played an important role in 
retardation of drug release. (38) 
 
4.1.5. Similarity factor (f₂) 
 
Table IV 
Dissolution data for calculating f₂ values 
 Referenc
e 
Test Referenc
e 
Test Referenc
e 
Test Reference Test 
Time 
(hr) 
Run 1 
Mean 
Run 4 
Mean 
Run 5 
Mean 
Run 8 
Mean 
Run 1 
Mean 
Run 5 
Mean 
Run 4 
Mean 
Run 8 
Mean 
1 30.09 29.55 63.22 84.63 30.09 63.22 29.55 84.63 
2 41.54 41.32 68.14 99.89 41.54 68.14 41.32 99.89 
3 48.53 48.91 99.14 99.99 48.53 99.14 48.91 99.99 
4 58.02 57.53 99.95 99.99 58.02 99.95 57.53 99.99 
 f₂ = 98.2 f₂ = 35.9 f₂ = 20.4 f₂ = 14.1 
Mean represents mean of 6 observations (released %) for every time point for each formulation. 
Similarity factor determination for different drug release profiles in the 
experimental design is depicted in Table IV. Similarity factor (f₂) for run 1 and run 
4 is 98.2. Both runs contain 100 mg insoluble drug (atenolol) and the same 
polymers with the same ratio (1:1). Two formulation runs have different polymers 
source (Chinese polymers for run 1 and German polymers for run 2), yet, they are 
comparable with regard to drug release profile (f₂ = 50-100). Consequently, the 
difference in polymers source has no (or a little) effect on dissolution behavior of 
tablets containing insoluble drug.  
For run 5 and run 8, f₂ is equal to 35.9 which support the non similarity. Although 
the condition of both formulations is similar to that of run 1 and 4, yet, drug 
solubility is different. This might indicate the effect the drug solubility might have 
on dissolution behavior,  
To illustrate the influence of drug solubility on dissolution of the drug from matrix 
system (3
rd
 factor in the experimental design), the f₂ value is calculated for run 1 
and run 5 (same polymers, same ratio and same source (China) and also for run 4 
and run 8 (same polymers, same ratio and same source (Germany), the calculated 
f₂ values are 20.4 and 14.1 respectively. The findings greatly support the fact that 
each pair of runs (1, 5) (4, 8) are significantly different with regard to drug release 
profiles and that the drug solubility is the main reason behind such dissimilarity. 
This is in agree with relevant published works concerning the influence of drug 
solubility on the drug release from glyceryl monooleate matrices (39), polyethylene 
glycol (40) and HPMC based matrices (41). 
4.2. Conclusion 
Based on the findings of this study, one might conclude that for insoluble drug, 
hydrophilic polymer has a profound effect on swelling profile of matrix systems 
compared to hydrophobic one. Moreover, variation in polymers source was shown 
to have a weighty impact on tablet hardness and drug release behavior of both 
soluble and insoluble drugs. Furthermore, the hydrophilic polymer was found to be 
more efficient, compared to hydrophobic polymer, in controlling drug dissolution 
rate and so the drug release kinetics of the matrix.  
In general, the solubility of the drug, solubility of the polymer and the source of the 
same material all have been shown to influence significantly the dissolution rate of 
a drug from matrix system.  
 
4.3. Recommendation 
Although, hydrophilic polymer has a profound effect on swelling profile of matrix 
systems compared to hydrophobic one, the researchers should still undergo some 
improvements for the role of hydrophobic polymers in controlling swelling 
behavior of matrix tablets. Also, the failure of chlorpheniramine maleate tablets to 
swell is expected to be due to the variation in drug source. So, I recommend more 
focusing in this manner. The effect of polymer source variation on physical 
performance of matrix tablet should be further linked by more researches with the 
influence on variation of drug (Active constituent) source. 
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